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Background
Modern antiretroviral therapy (ART) is assumed to allow
a certain degree of nonadherence while still maintaining
complete suppression of viral replication ("forgiveness”),
as virological suppression, measured by the commercial
plasma viral load assays, is common at adherence levels
>55-70% [1]. Yet, it is unknown whether HIV-1 replica-
tion is completely suppressed at these levels of adher-
ence. [2]Here we investigated whether modest non-
adherence to ART influences levels of HIV-1 RNA and
DNA in peripheral blood mononuclear cells (PBMC).
Materials and methods
Levels of HIV-1 unspliced RNA (usRNA) and viral DNA
were quantified by seminested real-time PCR [2-4] in
PBMC of 40 HIV-infected patients who had been on
successful ART for a median of 3.8 years before the
start of the study and with good immune reconstitution
(median baseline CD4
+ count, 620 cells/mm
3). For every
patient, three longitudinal samples, taken with 3-4
month intervals, were analyzed. One-week mean adher-
ence to ART (percentage of prescribed doses taken)
prior to the sampling moments was measured
electronically.
Results
Adherence never fell below7O% in any patient, and
concurrent plasma viral loads of 109/120 (91%) PBMC
samples were undetectable (<50 cop/ ml); for 10/11
remaining samples they were <100 cop/ml. Longitudin-
ally, 23 patients were constantly 100% adherent, eight
demonstrated improving adherence in time, and nine
("poor adherers”) showed decreasing, variable, or con-
stantly <100% adherence. Notwithstanding the lack of
virological rebound in any of the patients, poor adher-
ence, but not optimal or improving adherence, caused
a significant longitudinal increase in usRNA levels
(P=0.006). Remarkably, the change in adherence pat-
terns from optimal through improving to poor was
paralleled by a gradual increase in the corresponding
viral RNA trends. Significant differences between the
poor adherers and the remaining patients were
observed in time-weighted changes from baseline
(P=0.0006) and regression slopes (P=0.009) of usRNA,
but not of viral DNA. These effects were independent
of the therapy regimen or the time of virological sup-
pression. Same effects were observed in a subset of
patients whose plasma viremia was constantly unde-
tectable (n=30).
Conclusions
As ART only blocks the infection of new cells, but not
viral RNA transcription in infected cells, the observed
effect of decreased ART pressure (resulting from
decreased adherence) on HIV RNA levels in PBMC
strongly suggests new replication cycles despite ART,
and not simply enhanced HIV-1 transcription in cells
infected prior to therapy initiation. Our results represent
the first evidence indicating that constant optimal
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